VRTX Earnings Vertex Pharmaceuticals
Reported EPS, revenue and net income by fiscal period (SEC EDGAR) — quarterly and annual. Full financials → Chart & overview → Latest filing
Annual results
EPS
Revenue
Net income
Quarterly results
EPS
Revenue
Net income
Reported EPS history
1–60 of 60
| Q2 2026 | 2026-06-30 | 4.31 | 2026-08-04 | 10-Q |
| Q1 2026 | 2026-03-31 | 4.02 | 2026-05-05 | 10-Q |
| Q4 2025 (derived) | 2025-12-31 | 4.64 | 2026-02-13 | 10-K |
| FY 2025 | 2025-12-31 | 15.32 | 2026-02-13 | 10-K |
| Q3 2025 | 2025-09-30 | 4.20 | 2025-11-04 | 10-Q |
| Q2 2025 | 2025-06-30 | 3.99 | 2025-08-05 | 10-Q |
| Q1 2025 | 2025-03-31 | 2.49 | 2025-05-06 | 10-Q |
| Q4 2024 (derived) | 2024-12-31 | 3.62 | 2025-02-13 | 10-K |
| FY 2024 | 2024-12-31 | -2.08 | 2025-02-13 | 10-K |
| Q3 2024 | 2024-09-30 | 4.01 | 2024-11-05 | 10-Q |
| Q2 2024 | 2024-06-30 | -13.92 | 2024-08-02 | 10-Q |
| Q1 2024 | 2024-03-31 | 4.21 | 2024-05-07 | 10-Q |
| Q4 2023 (derived) | 2023-12-31 | 3.71 | 2024-02-15 | 10-K |
| FY 2023 | 2023-12-31 | 13.89 | 2024-02-15 | 10-K |
| Q3 2023 | 2023-09-30 | 3.97 | 2023-11-07 | 10-Q |
| Q2 2023 | 2023-06-30 | 3.52 | 2023-08-02 | 10-Q |
| Q1 2023 | 2023-03-31 | 2.69 | 2023-05-02 | 10-Q |
| Q4 2022 (derived) | 2022-12-31 | 3.14 | 2023-02-10 | 10-K |
| FY 2022 | 2022-12-31 | 12.82 | 2023-02-10 | 10-K |
| Q3 2022 | 2022-09-30 | 3.59 | 2022-10-28 | 10-Q |
| Q2 2022 | 2022-06-30 | 3.13 | 2022-08-05 | 10-Q |
| Q1 2022 | 2022-03-31 | 2.96 | 2022-05-06 | 10-Q |
| Q4 2021 (derived) | 2021-12-31 | 2.98 | 2022-02-09 | 10-K |
| FY 2021 | 2021-12-31 | 9.01 | 2022-02-09 | 10-K |
| Q3 2021 | 2021-09-30 | 3.28 | 2021-11-03 | 10-Q |
| Q2 2021 | 2021-06-30 | 0.26 | 2021-07-30 | 10-Q |
| Q1 2021 | 2021-03-31 | 2.49 | 2021-04-30 | 10-Q |
| Q4 2020 | 2020-12-31 | 2.30 | 2021-02-11 | 10-K |
| FY 2020 | 2020-12-31 | 10.29 | 2021-02-11 | 10-K |
| Q3 2020 | 2020-09-30 | 2.53 | 2020-10-30 | 10-Q |
| Q2 2020 | 2020-06-30 | 3.18 | 2020-07-31 | 10-Q |
| Q1 2020 | 2020-03-31 | 2.29 | 2020-05-01 | 10-Q |
| Q4 2019 | 2019-12-31 | 2.23 | 2020-02-13 | 10-K |
| FY 2019 | 2019-12-31 | 4.51 | 2020-02-13 | 10-K |
| Q3 2019 | 2019-09-30 | 0.22 | 2019-10-31 | 10-Q |
| Q2 2019 | 2019-06-30 | 1.03 | 2019-08-01 | 10-Q |
| Q1 2019 | 2019-03-31 | 1.03 | 2019-05-01 | 10-Q |
| Q4 2018 | 2018-12-31 | 5.97 | 2019-02-13 | 10-K |
| FY 2018 | 2018-12-31 | 8.09 | 2019-02-13 | 10-K |
| Q3 2018 | 2018-09-30 | 0.50 | 2018-10-25 | 10-Q |
| Q2 2018 | 2018-06-30 | 0.80 | 2018-07-26 | 10-Q |
| Q1 2018 | 2018-03-31 | 0.81 | 2018-04-27 | 10-Q |
| Q4 2017 | 2017-12-31 | 0.39 | 2018-02-15 | 10-K |
| FY 2017 | 2017-12-31 | 1.04 | 2018-02-15 | 10-K |
| Q3 2017 | 2017-09-30 | -0.41 | 2017-10-30 | 10-Q |
| Q2 2017 | 2017-06-30 | 0.07 | 2017-07-28 | 10-Q |
| Q1 2017 | 2017-03-31 | 0.99 | 2017-04-28 | 10-Q |
| Q4 2016 | 2016-12-31 | 0.13 | 2017-02-23 | 10-K |
| FY 2016 | 2016-12-31 | -0.46 | 2017-02-23 | 10-K |
| Q3 2016 | 2016-09-30 | -0.16 | 2016-10-31 | 10-Q |
| Q2 2016 | 2016-06-30 | -0.26 | 2016-08-01 | 10-Q |
| Q1 2016 | 2016-03-31 | -0.17 | 2016-05-03 | 10-Q |
| Q4 2015 (derived) | 2015-12-31 | -0.31 | 2016-02-16 | 10-K |
| FY 2015 | 2015-12-31 | -2.31 | 2016-02-16 | 10-K |
| Q3 2015 | 2015-09-30 | -0.39 | 2015-10-30 | 10-Q |
| Q2 2015 | 2015-06-30 | -0.78 | 2015-08-04 | 10-Q |
| Q1 2015 | 2015-03-31 | -0.83 | 2015-05-04 | 10-Q |
| Q4 2014 (derived) | 2014-12-31 | -0.74 | 2015-02-13 | 10-K |
| FY 2014 | 2014-12-31 | -3.14 | 2015-02-13 | 10-K |
| Q3 2014 | 2014-09-30 | -0.72 | 2014-11-06 | 10-Q |
Source: SEC EDGAR / XBRL (reported actuals; no consensus estimates). Some issuers (e.g. mortgage REITs, banks) don't report a conventional revenue line, so those charts may be omitted. Q4 EPS marked "derived" is computed as the fiscal-year EPS minus Q1–Q3 (10-Ks report only the annual figure); EPS is not strictly additive across quarters, so it can differ by a cent or two from the issuer's own Q4. A period with no "Reported" date is known only from a later filing's prior-year comparative. Informational only — not financial advice.